Buy Crypto Markets Spot FuturesBTC Earn Event Centre Rewards Hub

Inhibikase Therapeutics, Inc. (IKT)

NASDAQ

$2,35

$-0,00

(-0,21%)

Pre-Market

Inhibikase Therapeutics, Inc. (IKT) Live Price Chart

Last updated: ⁦2026-09-16 12:18:20⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Inhibikase Therapeutics, Inc. (IKT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2,35, with a market capitalisation of $333,49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,33 to $2,61. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$333,49M
Open	$2,36
Day's High	$70,80
Day's Low	$0,79
Previous Close	$2,31
Volume	242,00
Average Volume	752,09K
P/E Ratio	--
52-Week High	$2,61
52-Week Low	$1,33
Dividend Yield	--
Earnings Date	--

Inhibikase Therapeutics, Inc. (IKT) Pre-Market Stock Price

Inhibikase Therapeutics, Inc. (IKT) is trading at $2,35 in pre-market trading as of 2026-09-16 12:00:00, up 1,73% ($0,04) from the previous close of $2,31

Pre-market trading shows how investors are pricing IKT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.

Inhibikase Therapeutics, Inc. (IKT) 7-Day Stock Price Change

Over the past seven days, Inhibikase Therapeutics, Inc. (IKT) moved from $2,50 to $2,35, representing a decline of 6,00% ($0,15).

The stock traded between $2,25 and $2,55 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 354,33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

IKT 52-Week Price Position

Position in Range: 79,7%

52W Low$1,33

52W High$2,61

IKT is currently trading at $2,35, placing it 79,7% of the way from its 52-week low of $1,33 to its 52-week high of $2,61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Inhibikase Therapeutics, Inc. (IKT)?

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	35
Exchange	NASDAQ
Company Website	https://www.inhibikase.com

How to Buy Inhibikase Therapeutics, Inc. (IKT) Stock on MEXC

Eligible investors can buy real shares of Inhibikase Therapeutics, Inc. (IKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for IKT and Place Your Order

Open the RealStocks trading page and search for IKT. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Inhibikase Therapeutics, Inc. (IKT) stock price today?

Inhibikase Therapeutics, Inc. (IKT) is currently trading at $ 2,35, up 1,73% ($0,04) from the previous close of $ 2,31. Intraday prices update in real time during regular trading hours.

2.Is IKT stock going up or down today?

As of 2026-09-16 12:00:00, IKT is trading at $ 2,35, up 1,73% ($0,04) from its previous close of $ 2,31. The stock has traded between $ 0,79 and $ 70,80 during today’s regular session. Past price movements do not guarantee future results.

3.What is IKT pre-market price?

As of 2026-09-16 12:00:00, IKT is trading at $ 2,35 in pre-market trading, up 1,73% ($0,04) from the previous close of $ 2,31. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is IKT after-hours price?

As of 2026-09-16 12:00:00, IKT is trading at $ 2,36 in after-hours trading, up 1,95% ($0,04) from the regular-session close of $ 2,31. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is IKT stock trading now?

IKT trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does IKT sit relative to its 52-week high and low?

Over the past 52 weeks, IKT has traded between a low of $ 1,33 and a high of $ 2,61. At $ 2,35, the stock is positioned 79,7% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Inhibikase Therapeutics, Inc. in?

Inhibikase Therapeutics, Inc. (IKT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Inhibikase Therapeutics, Inc.'s market capitalisation and where is it listed?

Inhibikase Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 333,49M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is IKT valued in terms of P/E ratio and EPS?

IKT trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0,43. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Inhibikase Therapeutics, Inc. pay a dividend?

Inhibikase Therapeutics, Inc. pays an indicated annual cash dividend of $ 0,00 per share, with a current dividend yield of 0,00% based on the latest share price. Dividend policies are subject to change at the board's discretion.